Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | STK17A | Q9UEE5 | 11/20 | 0.55 |
| ▸ | STK17B | O94768 | 6/20 | 0.53 |
| ▸ | MEN1 | O00255 | 1/20 | 0.47 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.47 |
| ▸ | FERMT2 | Q96AC1 | 1/20 | 0.45 |
| ▸ | RHOC | P08134 | 1/20 | 0.45 |
| ▸ | RHOA | P61586 | 1/20 | 0.45 |
| ▸ | MAPT | P10636 | 2/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.43 |
| ▸ | PRSS1 | P07477 | 2/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11935538 | 0.92 | STK17A (0.52) | STK17ASTK17BMEN1KMT2AFERMT2 | |
| SCHEMBL4023262 | 0.92 | STK17A (0.52) | STK17ASTK17BMEN1KMT2AFERMT2 | |
| SCHEMBL11748511 | 0.89 | MAPT (0.52) | STK17AMAPTALDH1A1PRSS1 | |
| SCHEMBL656024 | 0.86 | STK17A (0.50) | STK17ASTK17BMEN1KMT2AFERMT2 | |
| SCHEMBL9639726 | 0.86 | MAPT (0.55) | MEN1KMT2ARHOCRHOAMAPT | |
| Hydrochloric Acid SCHEMBL28709080 | 0.84 | STK17A (0.49) | STK17ASTK17BMEN1KMT2AFERMT2 | |
| SCHEMBL7425672 | 0.80 | STK17A (0.51) | STK17ASTK17BMAPTALDH1A1PRSS1 | |
| SCHEMBL908984 | 0.80 | RHOC (0.46) | STK17ASTK17BMEN1KMT2ARHOC | |
| SCHEMBL9155154 | 0.80 | APP (0.52) | STK17AMAPTALDH1A1PRSS1 | |
| SCHEMBL3029679 | 0.79 | MEN1 (0.47) | MEN1KMT2ARHOCRHOAMAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120252792-A1 | METHODS AND COMPOSITIONS FOR MODULATING RHO-MEDIATED GENE TRANSCRIPTION | THE REGENTS OF THE UNIVERSITY OF MICHIGAN (US) | 2012-10-04 | — | — | US | disclosed |
| US-20120252792-A1 | METHODS AND COMPOSITIONS FOR MODULATING RHO-MEDIATED GENE TRANSCRIPTION | THE REGENTS OF THE UNIVERSITY OF MICHIGAN (US) | 2012-10-04 | — | — | US | disclosed |
| WO-2011035143-A2 | METHODS AND COMPOSITIONS FOR INHIBITING RHO-MEDIATED DISEASES AND CONDITIONS | THE REGENTS OF THE UNIVERSITY OF MICHIGAN (US) | 2011-03-24 | — | — | WO | disclosed |
| US-4264494-A | Chromium complex dyestuffs for natural polyamides and synthetic nylons | BASF AKTIENGESELLSCHAFT (DE) | 1981-04-28 | — | — | US | disclosed |
| US-4212801-A | Unsymmetrical 1:2-chromium complexes containing an azo and an azomethine bond | BASF AKTIENGESELLSCHAFT (DE) | 1980-07-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120252792-A1 | METHODS AND COMPOSITIONS FOR MODULATING RHO-MEDIATED GENE TRANSCRIPTION | RHOA, RHOC, ROCK1 | STK17A 2930/4885STK17B 2975/4885MEN1 3849/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.